Windward Bio (NASDAQ:WWB), a clinical-stage biotechnology company developing treatments for chronic inflammatory diseases, completed its first day of trading on the Nasdaq on November 13, 2026, with shares closing at $28.50, representing a 68% increase from its initial public offering price of $17.00 per share.
The closing price gave the company a market capitalisation of approximately $1.69 billion.
Founded in 2024, Windward Bio is focused on developing antibody-based therapies for respiratory and dermatological conditions, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.
The company’s public listing follows several private financing rounds involving institutional investors, including Qiming Venture Partners.
Qiming Venture Partners Participates in IPO Financing
Qiming Venture Partners, an existing investor in Windward Bio, participated in the company’s initial public offering financing round.
The investment firm previously backed Windward Bio through its Series A financing in 2025 and its Series B financing in 2026.
Windward Bio’s Nasdaq listing represents Qiming Venture Partners’ 11th portfolio company IPO during 2026.
The offering provides Windward Bio with a public market listing as it continues clinical development of its investigational antibody treatments.
WIN378 Under Evaluation in Asthma and COPD Clinical Trials
Windward Bio’s lead drug candidate, WIN378, is an investigational ultra-long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a protein involved in inflammatory responses.
The treatment is being developed for respiratory conditions associated with chronic inflammation.
WIN378 is currently being evaluated in two clinical studies.
The POLARIS-1 study is a Phase 2/3 clinical trial assessing the treatment in patients with severe uncontrolled asthma.
Separately, the SIRIUS study is a Phase 2 clinical trial investigating WIN378 in patients with chronic obstructive pulmonary disease.
Both studies form part of Windward Bio’s clinical development programme for the antibody candidate.
The company has not provided additional efficacy or safety results from these studies in the information accompanying the IPO announcement.
Windward Bio Holds Additional Bispecific Antibody Candidate
In addition to WIN378, Windward Bio’s development portfolio includes WIN027, a clinical-stage bispecific antibody licensed from Qyuns Therapeutics.
WIN027 targets both TSLP and interleukin-13 (IL-13), two proteins associated with inflammatory signalling.
The candidate forms part of the company’s broader research and development activities involving chronic inflammatory conditions.
Windward Bio also holds exclusive commercial and development rights to WIN378 across most international markets through a licensing agreement with Kelun-Biotech and Harbour BioMed.
The agreement excludes Greater China and certain other Asian countries, where the company does not hold exclusive rights.
These licensing arrangements establish the geographical scope of Windward Bio’s development and commercialisation rights for its lead treatment candidate.
Nasdaq Listing Supports Continued Clinical Development
Windward Bio’s market debut follows its establishment in 2024 and subsequent financing rounds in 2025 and 2026.
The company’s development activities remain centred on investigational antibody therapies, with WIN378 undergoing Phase 2/3 testing for severe uncontrolled asthma and Phase 2 testing for COPD.
Its additional clinical-stage candidate, WIN027, expands the company’s portfolio of treatments targeting inflammatory pathways.
Following the IPO, Windward Bio will continue operating as a publicly traded clinical-stage biotechnology company, with future development milestones dependent on the progress of its clinical programmes.
